DNMT3A (DNA methyltransferase 1)

In this exploratory pilot of 18 LCNEC cases, DNMT1 and DNMT3A transcripts were frequently higher relative to a normal-lung calibrator, while DNMT3B results were inconclusive due to technical limitations and small sample size. These descriptive findings warrant validation in larger, isoform-resolved cohorts before clinical inference. Future research should prioritize investigating these DNA methyltransferases to explore their therapeutic implications. Moreover, future research should also aim to detect and characterize individual DNMT3B isoforms in LCNEC patients to further elucidate their specific contributions to the pathology of the disease.

The RT-PCR analysis showed that the melatonin modulates the alterations in HDAC1, 2, 6, and 9 and DNMT1, DNMT3A and DNMT3B with respect to the control. The MS-PCR results signify one of the possible ways of action of melatonin on DL cells.

Polθ inhibitors enhance the anti-leukemic effects of standard drugs such as FLT3 kinase inhibitor quizartinib, cytarabine ± doxorubicin, and etoposide in vitro and in mice with DNMT3Amut leukemia. Altogether, Polθ is an attractive target in DNMT3Amut hematological malignancies.

P2, N=80, Recruiting, Mayo Clinic | Trial completion date: Mar 2027 --> Nov 2033 | Trial primary completion date: Mar 2027 --> Feb 2031

In a syngeneic immunocompetent glioblastoma mouse model, brain delivery of antisense oligonucleotide targeting Dnmt3a expression led to microglial activation and reduced tumor growth. Taken together, our results reveal the involvement of DNA demethylation in the control of glioma cells-induced microglia activation and indicate that microglial DNMT3A is a potentially therapeutic target to treat brain neoplasms such as glioblastoma that include a microglial component.

Greater understanding of clonal hematopoiesis in older patients could transform risk assessment and usher in personalized strategies to mitigate cardiovascular disease in our aging population. For the purposes of this review, we use "older adults" to refer to individuals aged ≥ 65 years (unless otherwise specified).

Based on Chinese AML patients as the study base, this study identifies independent prognostic factors affecting relapse after cytarabine consolidation therapy, and proposes a predictive model to assess the risk of early relapse in AML patients after receiving cytarabine consolidation therapy. This may provide a reference for clinicians to guide personalized treatment.

DNMT3B functions as a context-dependent epigenetic regulator linking enhancer-associated chromatin organization with proliferative control and apoptotic resistance in AML. DNMT3B-directed epigenetic perturbation remodels cis-regulatory circuitry and is associated with increased venetoclax responsiveness, supporting DNMT3B-governed networks as a candidate co-targeting axis in high-risk AML.

Our study establishes that CZ2, a novel organic arsenical, exhibits superior therapeutic efficacy and high selectivity in DLBCL by targeting DNMT. Our findings suggest that CZ2 represents a promising strategy to overcome epigenetic-mediated resistance, offering a potential therapeutic intervention for relapsed/refractory DLBCL and supporting its further development in rational combination regimens.

AML harbouring KMT2A-PTD frequently displays MR immunophenotypic abnormalities and is frequently associated with AML-MR type mutations. In addition, they have similar outcomes as compared with AML-MR.

And intraperitoneal administrating the inhibitor of EZH2 with GSK126 significantly ameliorated the nephritis in MRL/lpr mice. This research reveals a novel epigenetic regulation of JAM-A by EZH2-DNMT3A cascade contributes to T cell adhesion capacity via the activation of Rap1a/β1-integrin in lupus patients.

Notably, the SM component was negative for KIT D816V mutation, as expected for WD-SM; however, the immunophenotype was atypical with aberrant expression of CD25. This case highlights the potential for solid tumor genomics to expose occult myeloid neoplasms incidentally and underscores the importance of a comprehensive workup, including bone marrow examination, in distinguishing between incidental clonal hematopoiesis and bona fide myeloid neoplasms.